SCHEMBL4294895

SCHEMBL4294895

CC(CCc1ccccc1)c1c(O)c2ccccc2oc1=O

nearest known ligand 0.80

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 3/20 0.65
VKORC1 Q9BQB6 3/20 0.61
CYP2C9 P11712 7/20 0.60
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
ALB P02768 1/20 0.56
PCSK7 Q16549 1/20 0.56
HSD17B10 Q99714 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
CRHBP P24387 1/20 0.55
CASP7 P55210 1/20 0.55
CASP6 P55212 1/20 0.55
CRHR2 Q13324 1/20 0.55
HIF1A Q16665 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7354054 0.86 NQO1 (0.67) NQO1VKORC1CYP2C9KDM4EALDH1A1
SCHEMBL7352699 0.85 CYP2C9 (0.69) NQO1VKORC1CYP2C9KDM4EALDH1A1
SCHEMBL7351018 0.84 NQO1 (0.61) NQO1VKORC1CYP2C9KDM4EALDH1A1
SCHEMBL14078663 0.82 CYP2C9 (0.72) NQO1VKORC1CYP2C9CRHBPCASP7
SCHEMBL14078661 0.81 NQO1 (0.73) NQO1VKORC1CYP2C9CRHBPCASP7
SCHEMBL1647999 0.81 CYP2C9 (0.66) NQO1VKORC1CYP2C9KDM4EALDH1A1
SCHEMBL7358027 0.81 NQO1 (0.64) NQO1VKORC1CYP2C9KDM4EALDH1A1
SCHEMBL7358731 0.79 NQO1 (0.65) NQO1VKORC1CYP2C9KDM4EALDH1A1
SCHEMBL8042698 0.79 CYP2C9 (0.86) NQO1VKORC1CYP2C9KDM4EALDH1A1
SCHEMBL7072964 0.78 NQO1 (0.60) NQO1VKORC1CYP2C9KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209615-A1 INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209615-A1 INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS MMP9, MMP10, MMP17 NQO1 261/4885VKORC1 635/4885CYP2C9 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.